Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29
Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their first-time sponsorship of the 7th Annual Gene Therapy for Rare Disorders conference to be held March 26-29, 2024, in Boston, Massachusetts.
In keeping with their commitment to patient affordability and access, Paysign is sponsoring the annual event as an Exhibition Partner. The conference is the gene therapy industry’s leading event where key figures, service providers, payers and regulators discuss insights to the crucial challenges that face these programs today.
"We are thrilled to add this event to our annual schedule of sponsorships and to provide much-needed representation for patient affordability solutions that tackle the biggest issues facing access to gene therapy for rare disorders,” said Matthew Turner, President, Patient Affordability at Paysign.
Stop by and see the Paysign team at their booth to network and gain fundamental insights on how to mitigate barriers to patient access. To learn more about Paysign’s patient affordability solutions, visit paysign.com/rx.
Visit the Gene Therapy for Rare Disorders conference website to learn more and register for the event.
About Paysign
Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers and government institutions. Founded in 2001 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign’s end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, gift cards and countless other exchanges of value. Paysign’s solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.
Investor Relations
ir@paysign.com
888.522.4853
paysign.com/investors
Media Relations
Alicia Ches
702.749.7257
pr@paysign.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312706790/en/
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Apple Earnings: iPhone Growth Forecasts Drive Change in Fair Value
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted